Major-Company-Funded Drilling at This Sub-$1 Copper-Gold Explorer

Hey there, bargain hunter. Boston Scientific just handed you a blank page where guidance used to be, and the market is treating that blank page like a balance sheet catastrophe. It is not. But you do need to know exactly what you own before you decide what to do next.

Scoreboard

Boston Scientific disclosed it identified a cybersecurity incident on August 25 that affected certain IT systems and resulted in a global disruption to operations. In its September 8 Form 8-K, the company said it is unlikely to meet the net sales growth and adjusted EPS guidance it previously provided for Q3 and the full year 2026, and it intends to update its outlook on Wednesday, October 28, 2026. Reports at the time said the stock fell about 4.5% in premarket trading on the news. Citi responded by cutting its price target to $57 from $61. By Friday, September 11, BSX closed at about $43.10, near its 52-week low, and far below its 52-week high of $109.50.

What Actually Happened

Boston Scientific is unlikely to meet its net sales growth and adjusted EPS guidance ranges for Q3 and full-year 2026, which it provided in late July, roughly a month before the attack. That late-July guidance already reflected a trimmed outlook: management cut full-year organic revenue guidance to 5% to 6% and full-year adjusted EPS to $3.28 to $3.32, citing a sharp and unexpected slowdown in the U.S. WATCHMAN market and competitive pressure in Electrophysiology. The cyberattack is now punching a hole through even that reduced baseline.

Operationally, Boston Scientific has said its distribution network has been substantially restored and manufacturing has resumed across most facilities globally, but some business applications remain affected and full recovery timing is unknown. The company has also said it has seen no indication of unauthorized activity in its environment related to this incident since August 25, but that the investigation and full operational recovery remain incomplete.

The Business Underneath

Boston Scientific is a global medtech with two core segments: Cardiovascular and MedSurg. In Q2 2026, the company reported GAAP net income attributable to common stockholders of $907 million on sales of $5.442 billion, a 7.5% reported sales gain. MedSurg grew 5.9% in the quarter and Cardiovascular grew 8.3%. Cardiac rhythm management, electrophysiology, coronary interventions, and endoscopy are the core revenue engines. Stents, pacemakers, ablation catheters, and endoscopes do not stop being needed because an IT network went down for weeks.

Is It Cheap?

At roughly $43 a share, the stock is sitting near its 52-week low, and the uncertainty is doing a lot of the work in the valuation. Citi’s $57 target gives you one near-term anchor, while other firms have also trimmed targets since the cyber incident. Peers still command premium valuations when guidance is intact. BSX is priced today for a business in structural decline. The operational disruption is real, but the product line is not broken.

Bull / Base / Bear

• Bull: The backlog built during the shutdown ships in Q4, creating a revenue catch-up. Management resets realistic numbers on October 28 and guides conservatively. The stock re-rates toward $60 to $65 once the uncertainty is priced out.
• Base: Q3 comes in 10% to 15% below prior guidance. Full-year adjusted EPS lands somewhere below $3.28. The October 28 call provides a new floor, and the stock stabilizes in the mid-$40s through year-end.
• Bear: Recovery takes longer than expected. A second guidance cut follows in Q4. The company has said it is working to fulfill customer orders and reduce backlogs after the incident disrupted operations, and if hospital purchasing cycles shift to competitors during the disruption, some revenue is simply deferred or permanently lost.

Action Plan

Hold existing positions if your cost basis is below $55. Do not size up ahead of October 28: you are buying a known unknown. The rational entry for new capital is in two tranches: a small starter position now, with the second triggered only after management puts fresh numbers on the table at the Q3 report. Citi’s $57 target and BTIG’s $56 cut give you a rough analyst floor; the consensus average of $68 tells you where patient money could land over 12 months if execution normalizes.

Cheap Investor Checklist

• October 28 Q3 report: does management provide full new guidance or hedge again?
• Order backlog disclosure: how much deferred revenue gets shipped in Q4?
• Manufacturing uptime: any remaining sites still offline?
• WATCHMAN trajectory: is the softness structural or cyclical, independent of the cyberattack?
• Analyst target drift: do cuts cluster below $50 or hold above $55 post-October 28?
• Competitive share check: did Medtronic or Abbott pick up cardiac cases during the shipping gap?

Bottom Line

If October 28 brings a credible new guidance range and evidence the backlog is clearing, BSX at about $43 looks cheap for a business that generated $5.442 billion in quarterly revenue before anyone touched a keyboard maliciously. If management hedges again without numbers, the market will not forgive a second blank page. Wait for the October 28 reset before committing real size.